Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CENTRIFUGAL HEART-LUNG BYPASS PUMP SAFETY UNDER REVIEW BY REP. MURTHA

This article was originally published in The Gray Sheet

Executive Summary

CENTRIFUGAL HEART-LUNG BYPASS PUMP SAFETY UNDER REVIEW BY REP. MURTHA, according to a written statement released Oct. 6 by the Pennsylvania Democrat. Rep. John Murtha said that his office will meet with FDA to discuss the possibility of requiring "manufacturers of centrifugal pumps to develop safety systems or to add warning labels to the machines." He added that he will introduce legislation requiring manufacturers to add warning labels and safety features if FDA cannot act through existing regulations.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT002905

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel